Dr Pearse on the BOVen Trial of BTK Inhibitor Combinations in TP53-Mutant MCL
William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.
Source: onclive.com
Tp53 Mutation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tp53 Mutation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tp53 Mutation Today - Breaking & Trending Today
BOVen: Zanubrutinib, Obinutuzumab, and Venetoclax Yields 75% OS at 2 Years in High-Risk MCL
In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center presented phase 2 results for 25 patients with TP53 mutations.
Source: ajmc.com